J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling
Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.
You may also be interested in...
In Talc Litigation On ‘Baseless Scientific Claims,’ J&J Says Settlement Offers Plaintiffs 'Certainty’
Firm reiterates stance on safety of talc as it reports 7.4% Q1 growth in consumer health product sales contributes to earnings guidance boost. It reports $3.85bn consumer health sales with US sales up 11.4% to $1.74bn and international sales 4.4% to $2.12bn.
Plaintiffs’ attorneys blast J&J for reportedly considering weaseling out of its fiscal responsibilities by reorganizing its business away from talc liabilities, which could draw out tort proceedings and significantly reduce plaintiff awards, they suggest.
The Supreme Court said on 1 June that it would not review a $2bn verdict in Missouri for 22 women who alleged links between ovarian cancer and asbestos-tainted talc in Johnson’s Baby Powder. J&J believes the US' top court passed on an "extraordinary opportunity" that "leaves unresolved significant legal questions that state and federal courts will continue to face."